Opinion|Videos|June 18, 2024
Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care
The panelists share their concluding thoughts on the importance of collaboration between academic and community practices to achieve the best outcomes for their patients, which includes seeking second opinions and incorporating insights from tumor board discussions.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- When a new eBC product is approved, what is done prior to prepare from an operational standpoint?
- Are there instances when a new eBC product is approved and it’s not worth operationalizing?
- How can academic centers work efficiently with community practices in the management of patients with eBC?
- Scimeca: How might the approval of targeted therapies affect treatment paradigms for eBC?
Advertisement
Related to this article
As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Precision in Practice: Biomarker Testing and Treatment Selection in Primary Advanced or Recurrent Endometrial Cancer
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5